Stocks of Claris Lifesciences surged nearly 18 per cent amid reports that Cadila Healthcare has emerged as the front runner to acquire the generic sterile injectables business of the company.
The stock soared 17.79 per cent to Rs 331 on the BSE.
On the volume front, 17.76 lakh shares of the company were traded in early deals at the NSE.
As per reports, Cadila Healthcare has emerged as the front runner to acquire the generic sterile injectables business of Claris Lifesciences (CLL) trumping several domestic and global peers who were also interested in the asset.
Cadila is likely to pay a hefty premium, valuing the company at Rs 3,100-3,400 crore, the reports said.
Meanwhile, the BSE has sought clarification from Claris Lifesciences with reference to reports that Cadila is eyeing Claris arm for Rs 3,400 crore.
